DE2707881C2 - Verfahren zum Nachweis von rheumatoiden Faktoren - Google Patents

Verfahren zum Nachweis von rheumatoiden Faktoren

Info

Publication number
DE2707881C2
DE2707881C2 DE2707881A DE2707881A DE2707881C2 DE 2707881 C2 DE2707881 C2 DE 2707881C2 DE 2707881 A DE2707881 A DE 2707881A DE 2707881 A DE2707881 A DE 2707881A DE 2707881 C2 DE2707881 C2 DE 2707881C2
Authority
DE
Germany
Prior art keywords
immunoglobulin
igg
aggregated
analytically detectable
rheumatoid factors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE2707881A
Other languages
German (de)
English (en)
Other versions
DE2707881A1 (de
Inventor
Roger Upplands Bälinge Hällgren
Leif Edvin Uppsala Wide
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phadia AB
Original Assignee
Pharmacia Diagnostics AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Diagnostics AB filed Critical Pharmacia Diagnostics AB
Publication of DE2707881A1 publication Critical patent/DE2707881A1/de
Application granted granted Critical
Publication of DE2707881C2 publication Critical patent/DE2707881C2/de
Expired legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/962Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/80Fluorescent dyes, e.g. rhodamine
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/804Radioisotope, e.g. radioimmunoassay
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/819Multifunctional antigen or antibody
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/821Chemistry: analytical and immunological testing involving complement factors or complement systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/826Additives, e.g. buffers, diluents, preservatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Rehabilitation Therapy (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DE2707881A 1976-09-08 1977-02-24 Verfahren zum Nachweis von rheumatoiden Faktoren Expired DE2707881C2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE7609906A SE441042B (sv) 1976-09-08 1976-09-08 Sett att pavisa rheumatoida faktorer

Publications (2)

Publication Number Publication Date
DE2707881A1 DE2707881A1 (de) 1978-03-09
DE2707881C2 true DE2707881C2 (de) 1985-05-30

Family

ID=20328828

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2707881A Expired DE2707881C2 (de) 1976-09-08 1977-02-24 Verfahren zum Nachweis von rheumatoiden Faktoren

Country Status (8)

Country Link
US (1) US4153417A (cg-RX-API-DMAC7.html)
JP (1) JPS6057544B2 (cg-RX-API-DMAC7.html)
CA (1) CA1076937A (cg-RX-API-DMAC7.html)
DE (1) DE2707881C2 (cg-RX-API-DMAC7.html)
FR (1) FR2364456A1 (cg-RX-API-DMAC7.html)
GB (1) GB1576400A (cg-RX-API-DMAC7.html)
NL (1) NL7708078A (cg-RX-API-DMAC7.html)
SE (1) SE441042B (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4302536A (en) * 1978-08-15 1981-11-24 Longenecker Robert W Colorimetric immunoassay process
US4342566A (en) * 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4434227A (en) * 1982-02-08 1984-02-28 Abbott Laboratories Immunoassay for class specific immunoglobulin antibodies
US4450231A (en) * 1982-03-31 1984-05-22 Biostar Medical Products, Inc. Immunoassay for determination of immune complexes with polymer-coated plastic base
US4582793A (en) * 1982-10-29 1986-04-15 Research Corporation Anti-RNA polymerase I antibody test for the diagnosis of rheumatological diseases
SE8304836D0 (sv) * 1983-09-09 1983-09-09 Pharmacia Ab Sett att bestemma forendringar i ledbrosk
CA1261257A (en) * 1984-09-19 1989-09-26 Helgi Valdimarsson Prognostic value of rheumatoid factor isotypes and their association with disease activity
US4914041A (en) * 1988-02-12 1990-04-03 Beckman Instruments, Inc. Reagent and method for detecting rheumatoid factor
DE68924783T2 (de) * 1988-09-30 1996-03-28 Neorx Corp Wässrige additivsysteme, verfahren und polymerteilchen.
US5066789A (en) * 1988-09-30 1991-11-19 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages
US4986979A (en) * 1989-03-14 1991-01-22 Neorx Corporation Imaging tissue sites of inflammation
JPH02144560U (cg-RX-API-DMAC7.html) * 1989-05-12 1990-12-07
US6300480B1 (en) 1996-11-08 2001-10-09 Matsushita Electric Industrial Co., Ltd. Dye-labeled protein conjugate and method for preparing the same
JPH11322798A (ja) * 1998-05-14 1999-11-24 Matsushita Electric Ind Co Ltd 色素標識重合抗体およびその製造方法
US6303758B1 (en) 1996-11-08 2001-10-16 Matsushita Electric Industrial Co., Ltd. Dye-labeled and polymerized antibody and method for preparing the same
JP3601972B2 (ja) * 1998-05-14 2004-12-15 松下電器産業株式会社 色素標識タンパク質複合体およびその製造方法
JP3625250B2 (ja) * 1998-05-14 2005-03-02 松下電器産業株式会社 色素標識重合抗体およびその製造方法
US6303759B1 (en) 1996-11-08 2001-10-16 Matsushita Electric Industrial Co., Ltd. Dye-labeled and polymerized antibody and method for preparing the same
BR0017261A (pt) 2000-07-14 2003-07-29 Immunivest Corp Métodos para isolamento de uma bioentidade alvo de uma amostra biológica e de células de tumor com densidade de antìgeno baixa e, kits para inibir a agregação endógena de partìculas magnéticas coloidais no processamento de material biológico e, para isolamento de células de tumor de densidade de antìgeno baixa de uma amostra biológica com agregação ontrolada de partìculas magnéticas coloidais
US20060159680A1 (en) * 2005-01-14 2006-07-20 Smith Henry J Targeted apherisis for the treatment of rheumatoid arthritis
US20130068691A1 (en) * 2011-08-05 2013-03-21 Henry John Smith Targeted apheresis for the treatment of rheumatoid arthritis and immune disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1484727A (fr) * 1966-04-19 1967-06-16 Réactif immunologique et son procédé d'obtention
GB1179435A (en) * 1966-06-17 1970-01-28 Ortho Pharma Corp Stable Reagent for the Detection of Rheumatoid Arthritis
US3689632A (en) * 1969-01-06 1972-09-05 Kowa Co Rheumatoid agglutination test and reagent
GB1508132A (en) * 1974-05-20 1978-04-19 Technicon Instr Analysis of biological fluids

Also Published As

Publication number Publication date
SE441042B (sv) 1985-09-02
JPS6057544B2 (ja) 1985-12-16
DE2707881A1 (de) 1978-03-09
JPS5334918A (en) 1978-03-31
SE7609906L (sv) 1978-03-09
FR2364456B1 (cg-RX-API-DMAC7.html) 1981-08-28
US4153417A (en) 1979-05-08
CA1076937A (en) 1980-05-06
NL7708078A (nl) 1978-03-10
FR2364456A1 (fr) 1978-04-07
GB1576400A (en) 1980-10-08

Similar Documents

Publication Publication Date Title
DE2707881C2 (de) Verfahren zum Nachweis von rheumatoiden Faktoren
DE2806146C2 (de) Tumor-spezifisches Glykoprotein und dessen Verwendung zur Krebsdiagnose beim Menschen
DE2029499C3 (de) Verfahren zum Nachweis der Anwesenheit von carcinoembryonalen Antigenen im Blut
DE2126680A1 (de) Carcinoembryonisches Antigen
DE1598945A1 (de) Verfahren zur Bestimmung von Proteinen und Polypeptiden
DE2403994A1 (de) Herstellung von antisera
DE2707913C2 (de) Verfahren zum Nachweis von rheumatoiden Faktoren
DE2934757C2 (de) Zusammensetzung und Verfahren zur Bestimmung von Humanimmunglobulin-G
CH625345A5 (cg-RX-API-DMAC7.html)
DE2934756C2 (de) Zusammensetzung zur Bestimmung von beta 2 -Humanmikroglobulin und Verfahren zu deren Herstellung und deren Anwendung
CH630643A5 (en) Process for concentrating a placenta-specific glycoprotein.
DE2310280A1 (de) Tubocurarin-antigene
DE3887727T2 (de) Partikelstabilisierte Epitope zur Standardisierung und Kontrolle von Immuntests.
DE3024270C2 (de) Zusammensetzung zur Bestimmung des menschlichen Erythropoietins und Verfahren zu dessen Bestimmung
DE2126128A1 (de) Medizinisches Testverfahren, Reagens und Additiv zur Durchführung des Verfahrens
EP0156266A2 (de) Gewebeprotein PP21, Verfahren zu seiner Gewinnung sowie seine Verwendung
DE2243237A1 (de) Nachweis der immunreaktion gegenueber krebs
DE3872235T2 (de) Allgemeiner krebsverbundener faktor, durch scm erkannt, seine praeparation und sein verwendungsverfahren.
DE2445677C2 (de) Hochmolekulares alpha-Globulin und Verfahren zu dessen Herstellung
DE2748520A1 (de) Hepatitis b-dane-teilchen
DE3511199A1 (de) Verfahren zur immunologischen bestimmung von heparansulfat-proteoglykan, verfahren zur herstellung bzw. reinigung von dafuer geeignetem heparansulfat-proteoglykan aus basalmembran-haltigen geweben
DE2539219A1 (de) Radioimmunologisches untersuchungsverfahren zur in-vitro-bestimmung der renin-aktivitaet und besteck zur durchfuehrung dieses verfahrens
AT208507B (de) Verfahren zur Herstellung einer stabilen hitzeinaktivierbaren Proteinlösung
DE2117473A1 (de) Serodiagnostisches Präparat
DE2602892A1 (de) Konzentriertes hepatitis-b-oberflaechenantigen enthaltende masse und verfahren zu ihrer herstellung

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
D2 Grant after examination
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee